|
1.
|
|
9 p, 745.8 KB |
The EMIF-AD Multimodal Biomarker Discovery study : Design, methods and cohort characteristics
/
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie (Maastricht University) ;
Vandenberghe, Rik (Katholieke Universiteit Leuven) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Engelborghs, Sebastiaan (University of Antwerp) ;
Frisoni, Giovanni (IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli) ;
Molinuevo, José Luis (Fundació Pasqual Maragall) ;
Wallin, Anders (Institute of Neuroscience and Physiology) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Lausanne University Hospital) ;
Martinez-Lage, Pablo (Centro de Investigación y Tecnología Agroalimentaria de Aragón) ;
Baird, Alison (University of Oxford) ;
Dobson, Richard (NIHR University College London Hospitals) ;
Legido-Quigley, Cristina (King's College London) ;
Sleegers, Kristel (University of Antwerp) ;
Van Broeckhoven, Christine (University of Antwerp) ;
Bertram, Lars (University of Oslo) ;
Ten Kate, Mara (Amsterdam UMC. University Medical Center) ;
Barkhof, Frederik (Amsterdam UMC. University Medical Center) ;
Zetterberg, Henrik (UK Dementia Research Institute) ;
Lovestone, Simon (University of Oxford) ;
Streffer, Johannes (Janssen Pharmaceutical Companies) ;
Visser, Pieter Jelle (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer's disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. [...]
2018 -  10.1186/s13195-018-0396-5
Alzheimer's research & therapy, Vol. 10 Núm. 1 (june 2018) , p. 64
|
|
|
2.
|
|
12 p, 1.2 MB |
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease
/
Startin, Carla M. (LonDownS Consortium (London Down Syndrome Consortium)) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Hamburg, Sarah (LonDownS Consortium (London Down Syndrome Consortium)) ;
Hithersay, Rosalyn (LonDownS Consortium (London Down Syndrome Consortium)) ;
Wiseman, Frances K. (University College London) ;
Mok, Kin Y. (Hong Kong University of Science and Technology) ;
Hardy, John (University College London) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Lovestone, Simon (University of Oxford) ;
Parnetti, Lucilla (University of Perugia) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Hye, Abdul (Maudsley NHS Foundation) ;
Fisher, Elisabeth ;
Nizetic, Dean ;
Tybulewicz, Victor ;
Karmiloff-Smith, Anette ;
Al-Janabi, Tamara ;
Zhang, David ;
Strydom, André (LonDownS Consortium (London Down Syndrome Consortium)) ;
Universitat Autònoma de Barcelona
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. [...]
2019 - 10.1186/s13195-019-0477-0
Alzheimer's research & therapy, Vol. 11 Núm. 1 (21 2019) , p. 26
|
|
|
3.
|
|
9 p, 1012.4 KB |
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : A cross-sectional analysis from the AB255 Study
/
Pérez-Grijalba, Virginia (Araclon Biotech S.L.) ;
Arbizu, Javier (Clínica Universidad de Navarra) ;
Romero, Judith (Araclon Biotech S.L.) ;
Prieto, Elena (Clínica Universidad de Navarra) ;
Pesini, Pedro (Araclon Biotech S.L.) ;
Sarasa, Leticia (Araclon Biotech S.L.) ;
Guillen, Fernando (Clínica Universidad de Navarra) ;
Monleón, Inmaculada (Araclon Biotech S.L.) ;
San-José, Itziar (Araclon Biotech S.L.) ;
Martínez-Lage, Pablo (Fundación CITA-Alzheimer) ;
Munuera, Josep (Institut de Recerca Sant Joan de Déu) ;
Hernández, Isabel (Instituto de Salud Carlos III) ;
Buendía, Mar (Universitat Internacional de Catalunya) ;
Sotolongo-Grau, Oscar (Universitat Internacional de Catalunya) ;
Alegret, Montserrat (Instituto de Salud Carlos III) ;
Ruiz, Agustín (Instituto de Salud Carlos III) ;
Tárraga, Lluís (Instituto de Salud Carlos III) ;
Boada, Mercè (Instituto de Salud Carlos III) ;
Sarasa, Manuel (Araclon Biotech S.L.) ;
Goñi Imízcoz, Miguel (Hospital Divino Vallés (Burgos)) ;
Pujadas, Francesc ;
Villarejo, Alberto ;
Frank, Ana ;
Peña-Casanova, Jordi ;
Fernández, Manuel ;
Piñol, Gerard ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Gil, Pedro ;
Pascual, Luis F. ;
Aguilar Barberà, Miquel ;
Frisoni, Giovanni B. ;
Matias-Guiu, Jorge ;
Andreasen, Niels ;
Antúnez, Carmen ;
Universitat Autònoma de Barcelona
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. [...]
2019 - 10.1186/s13195-019-0549-1
Alzheimer's research & therapy, Vol. 11 Núm. 1 (january 2019) , p. 96
|
|
|
4.
|
|
11 p, 1.4 MB |
APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease
/
Konijnenberg, Elles (Alzheimer Center Amsterdam) ;
Tijms, Betty M. (Alzheimer Center Amsterdam) ;
Gobom, Johan (University of Gothenburg) ;
Dobricic, Valerija (University of Lübeck) ;
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie (Maastricht University) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Popp, Julius (Lausanne University Hospital) ;
Martinez-Lage, Pablo (CITA-Alzheimer Foundation) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Frölich, Lutz (University of Heidelberg) ;
Lovestone, Simon (Janssen RandD) ;
Streffer, Johannes (Janssen RandD) ;
Bertram, Lars (University of Oslo) ;
Blennow, Kaj (University of Gothenburg) ;
Teunissen, Charlotte E. (Vrije Universiteit Amsterdam) ;
Veerhuis, Robert (Vrije Universiteit Amsterdam) ;
Smit, August B. (Vrije Universiteit Amsterdam) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Zetterberg, Henrik (UK Dementia Research Institute) ;
Visser, Pieter Jelle (Karolinska Instutet) ;
Universitat Autònoma de Barcelona
Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer's disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprotein E (APOE) ϵ4 genotype plays a major role. [...]
2020 - 10.1186/s13195-020-00628-z
Alzheimer's research & therapy, Vol. 12 Núm. 1 (27 2020) , p. 65
|
|
|
5.
|
|
4 p, 880.7 KB |
β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer's disease
/
Mohaupt, Pablo (Université de Montpellier) ;
Pons, Marie-Laure (Université de Montpellier) ;
Vialaret, Jérôme (Université de Montpellier) ;
Delaby, Constance (Institut d'Investigació Biomèdica Sant Pau) ;
Hirtz, Christophe (Université de Montpellier) ;
Lehmann, Sylvain (Université de Montpellier) ;
Universitat Autònoma de Barcelona
Synaptic degeneration is an early event closely associated with the course of Alzheimer's disease (AD). The identification of synaptic blood biomarkers is, therefore, of great interest and clinical relevance. [...]
2022 - 10.1186/s13195-022-01125-1
Alzheimer's research & therapy, Vol. 14 (november 2022)
|
|
|
6.
|
|
19 p, 3.1 MB |
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients
/
Lennol, Matthew Paul (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Sánchez-Domínguez, Irene (Universitat de Barcelona. Institut de Neurociències) ;
Cuchillo-Ibañez, Inmaculada (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Camporesi, Elena (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ;
Brinkmalm, Gunnar (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Soria, Guadalupe (Universitat de Barcelona. Laboratori de Neuroanatomia Quirúrgica. Facultat de Medicina i Ciències de la Salut) ;
Aguado, Fernando (Universitat de Barcelona. Institut de Neurociències) ;
Zetterberg, Henrik (Hong Kong Center for Neurodegenerative Diseases) ;
Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ;
Sáez-Valero, Javier (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Universitat Autònoma de Barcelona
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. [...]
2022 - 10.1186/s13195-022-01108-2
Alzheimer's research & therapy, Vol. 14 Núm. 1 (december 2022) , p. 161
|
|
|
7.
|
|
13 p, 3.8 MB |
Cortical microstructure in primary progressive aphasia : a multicenter study
/
Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ;
Borrego-Écija, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mandelli, Maria Luisa (University of California. Memory and Aging Center) ;
Falgàs, Neus (University of California. Memory and Aging Center) ;
Welch, Ariane E. (University of California. Memory and Aging Center) ;
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Santos-Santos, Miguel Angel (Institut d'Investigació Biomèdica Sant Pau) ;
Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Dols Icardo, Oriol (Institut d'Investigació Biomèdica Sant Pau) ;
Belbin, Olivia (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez-Saudinós, María Belén (Institut d'Investigació Biomèdica Sant Pau) ;
Bargalló, Núria (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
González-Ortiz, Sofía (Hospital del Mar (Barcelona, Catalunya)) ;
Lladó, Albert (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Blesa, Rafael (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Dickerson, Bradford C. (Massachusetts Alzheimer's Disease Research Center) ;
Rosen, Howard J. (University of California. Memory and Aging Center) ;
Miller, Bruce L. (University of California, San Francisco (UCSF)) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Gorno-Tempini, Maria Luisa (University of California. Department of Neurology) ;
Sanchez-Valle, Raquel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau)
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. [...]
2022 - 10.1186/s13195-022-00974-0
Alzheimer's research & therapy, Vol. 14 Núm. 1 (december 2022) , p. 27
|
|
|
8.
|
|
10 p, 1.5 MB |
Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease
/
Benejam, Bessy (Fundació Catalana Síndrome de Down) ;
Aranha, Mateus (Institut d'Investigació Biomèdica Sant Pau) ;
Videla Toro, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Padilla, Concepción (Institut d'Investigació Biomèdica Sant Pau) ;
Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández, Susana (Barcelona Down Medical Center. Fundació Catalana Síndrome de Down) ;
Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau) ;
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ;
Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Iulita, M. Florencia (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ;
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ;
Giménez, Sandra (Institut d'Investigació Biomèdica Sant Pau) ;
González-Ortiz, Sofía (Parc de Salut MAR de Barcelona) ;
Videla, Sebastián (Institut d'Investigació Biomèdica de Bellvitge) ;
Bartrés-Faz, David (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Blesa, Rafael (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. [...]
2022 - 10.1186/s13195-022-01064-x
Alzheimer's research & therapy, Vol. 14 Núm. 1 (december 2022) , p. 123
|
|
|
9.
|
|
15 p, 2.2 MB |
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
/
Lantero-Rodríguez, Juan (University of Gothenburg) ;
Vrillon, Agathe (Groupe Hospitalo Universitaire Assistance Publique Hôpitaux de Paris Nord Hôpital Lariboisière Fernand-Widal) ;
Fernández-Lebrero, Aida (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ortiz-Romero, Paula (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Snellman, Anniina (University of Turku) ;
Montoliu-Gaya, Laia (the Sahlgrenska Academy at the University of Gothenburg) ;
Brum, Wagner S. (Universidade Federal do Rio Grande do Sul (UFRGS)) ;
Cognat, Emmanuel (Groupe Hospitalo Universitaire Assistance Publique Hôpitaux de Paris Nord Hôpital Lariboisière Fernand-Widal) ;
Dumurgier, Julien (Groupe Hospitalo Universitaire Assistance Publique Hôpitaux de Paris Nord Hôpital Lariboisière Fernand-Widal) ;
Puig-Pijoan, Albert (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Navalpotro-Gómez, Irene (Institut Hospital del Mar d'Investigacions Mèdiques) ;
García-Escobar, Greta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Karikari, Thomas K. (University of Pittsburgh) ;
Vanmechelen, Eugeen (ADx NeuroSciences (Ghent, Bèlgica)) ;
Ashton, Nicholas J. (NIHR Biomedical Research Centre for Mental Health (Londres, Regne Unit)) ;
Zetterberg, Henrik (University of Wisconsin School of Medicine and Public Health) ;
Suárez-Calvet, Marc (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Paquet, Claire (Groupe Hospitalo Universitaire Assistance Publique Hôpitaux de Paris Nord Hôpital Lariboisière Fernand-Widal) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia))
Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer's disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. [...]
2023 - 10.1186/s13195-023-01201-0
Alzheimer's research & therapy, Vol. 15 (march 2023)
|
|
|
10.
|
|
10 p, 855.6 KB |
Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy
/
De Kort, A.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Kuiperij, H.B. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Kersten, I. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Versleijen, A.A.M. (Department of Laboratory Medicine. Radboud University Medical Center) ;
Greenberg, S.M. (Massachusetts General Hospital (Boston)) ;
Stoops, E. (ADx NeuroSciences) ;
Schreuder, F.H.B.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Klijn, C.J.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Claassen, Jurgen A. H. R (Radboud University Medical Centre. Department of Geriatrics) ;
Verbeek, M.M. (Department of Laboratory Medicine. Radboud University Medical Center) ;
Universitat Autònoma de Barcelona
Background: Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to amyloid β-induced cell death. [...]
2021 - 10.1186/s13195-021-00899-0
Alzheimer's research & therapy, Vol. 13 Núm. 1 (december 2021) , p. 160
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
